Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
8
×
Tags
clinical trials
8
×
life sciences
national blog main
8
×
boston blog main
boston top stories
boston
national top stories
biotech
drugs
new york blog main
san francisco blog main
fda
patisiran
rna interference
san diego blog main
san francisco top stories
akcea therapeutics
alnylam pharmaceuticals
atlas venture
deals
gene therapy
inotersen
new york top stories
onpattro
regeneron pharmaceuticals
san diego top stories
startups
tafamidis
acute hepatic porphyrias
adeno-associated virus
akin akinc
alexion pharmaceuticals
allosteric
alnylam pharmaceutials
aminolevulinic acid
anylam pharmaceuticals
arrowhead pharmaceuticals
astellas pharma
atopic dermatitis
audentes therapeutics
What
ago
8
×
medicines
drug
fda
alnylam
medicine
rare
rna
therapeutics
approved
battle
data
disease
genetic
interference
long
patients
pharmaceuticals
rnai
sets
weeks
years
abandoning
adding
address
adds
aiming
akcea
allosteric
amyloidosis
approval
approve
attr
available
awaits
baggage
balance
biological
biotechs
build
Language
unset
Current search:
photo
×
" national blog main "
×
" clinical trials "
×
ago
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug